Significant Achievements

IBD (TPMT and NUDT15 testing)

Variants in TPMT and NUDT15 genes can identify patients at risk of Leucopenia, one of the major adverse events leading to discontinuation of treatment in a specific subset of IBD patients Genotyping for variants in these genes before initiation of treatment can prioritize the patients and minimize side effects.

 

Diabetes and Islet Biology

We indigenously developed a biomimetic natural proteinaceous device for effective transplantation of islet cells to treat diabetic patients.

 

Genetics of Pancreatic Diseases

Based on the research work carried out over the years, we offer a gene panel that tests 13 variants in genes namely SPINK1, PRSS1, CTRC, CTSB, CFTR, MORC4, and BACH2. The variant status in a patient indicates the genetic predisposition for idiopathic Chronic pancreatitis.

 

UGT1A1 Genotyping in Gilberts Syndrome

Gilberts syndrome is a relatively mild condition with elevated levels of bilirubin (hyperbilirubinemia).  We screen for two variants TA repeats and G71R of the UGT1A1 gene, which provides instructions to make the enzyme bilirubin uridine diphosphate glucuronosyltransferase (bilirubin-UGT) for the removal of bilirubin from the body. Variants in the promoter region of the gene confirm Gilbert’s Syndrome.

 

Pharmacogenomics

Gene testing for the recommendation of suitable doses of medications before initiation of treatment in a patient, based on the variant in genes namely CYP2C19 for Clopidogrel & Proton Pump Inhibitors (PPIs), CYP3A5 for Tacrolimus, VKORC1, and CYP2C9 for Warfarin.